Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy

PURPOSE: The 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline on HER2 testing in breast cancer permits reclassification of cases with HER2-equivocal results by FISH. The impact of such reclassification is unclear. We sought to determine the proportion...

Descripción completa

Detalles Bibliográficos
Autores principales: Crespo, James, Sun, Hongxia, Wu, Jimin, Ding, Qing-Qing, Tang, Guilin, Robinson, Melissa K., Chen, Hui, Sahin, Aysegul A., Lim, Bora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660495/
https://www.ncbi.nlm.nih.gov/pubmed/33180796
http://dx.doi.org/10.1371/journal.pone.0241775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660495/
https://www.ncbi.nlm.nih.gov/pubmed/33180796
http://dx.doi.org/10.1371/journal.pone.0241775

Ejemplares similares